Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Not Applicable

Not yet recruiting

• Conditions: Hypertension; Uncontrolled Hypertension
• Interventions: Drug: iloperidone; Drug: Placebo

• Registration Number: NCT07090161
• Lead Sponsor: Vanda Pharmaceuticals

Brief Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-22
• Study First Submitted QC: 2025-07-22
• Last Update Submitted: 2025-07-22
• Study Start: 2025-07-28
• Study First Posted: 2025-07-29
• Last Update Posted: 2025-07-29
• Primary Completion: 2026-10
• Study Completion: 2026-11-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies

Exclusion Criteria

• Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental/Iloperidone	iloperidone	-
Placebo Comparator	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change from baseline to treatment week 4 in SiSBP	screening to treatment week 4